SENATE-BILL 3302: S.3302 - Mikaela Naylon Give Kids a Chance Act of 2025
AI-Powered Summary
SENATE-BILL 3302 aims to enhance the research and development of drugs specifically for pediatric cancer, addressing a critical gap in medical research for children. The legislation emphasizes the need for pediatric patients to be included in drug development processes, thereby improving access to effective treatments for this vulnerable population. Major themes include health care rights, parental authority in medical decisions, and the separation of powers concerning regulatory authority. Key provisions involve amending the Federal Food, Drug, and Cosmetic Act to facilitate pediatric cancer drug investigations, establishing requirements for meaningful data collection, and tasking the Secretary of Health and Human Services with issuing guidance and conducting studies to assess the effectiveness of these amendments. The bill also extends priority review vouchers to incentivize the development of drugs for rare pediatric diseases. Implementation requirements include the Secretary's guidance and studies, which will influence future drug development and availability. The potential impacts include improved health outcomes for pediatric cancer patients, increased access to necessary treatments, and possible concerns regarding equity in drug prioritization and the delegation of regulatory authority.
Demographic Impact Analysis
Summary
Overall Constitutional Implications
The bill has significant positive implications for individual rights, particularly for children diagnosed with cancer. By focusing on pediatric-specific treatments, it addresses a critical gap in healthcare that has historically marginalized this demographic.
Key Individual Rights
- Right to Health Care
- Equal Protection under the Law
- Parental Rights in Medical Decisions
Constitutional Provisions
- Fourteenth Amendment - Right to Life and Liberty
- Fourteenth Amendment - Equal Protection Clause
- Due Process Clause
Potential Constitutional Challenges Or Support
While the bill is largely supportive of constitutional principles, challenges may arise regarding the adequacy of protections for children in clinical trials. Ensuring robust informed consent processes and equitable access across demographic lines will be crucial to avoid potential equal protection issues.
Summary
SENATE-BILL 3302 aims to enhance research and development of pediatric cancer treatments, directly impacting the health outcomes of children. By mandating age-appropriate formulations and prioritizing access to new therapies, the bill supports the rights of vulnerable populations, particularly children, to receive effective medical care. However, careful implementation is necessary to ensure that it does not inadvertently create disparities among different demographic groups.
Constitutional Analysis
This bill appears to align with constitutional principles. The proposed legislation operates within the established framework of constitutional authority and does not appear to conflict with fundamental rights or the separation of powers.
Analysis generated using AI-powered review of constitutional principles and legal precedents.
Take Action
Text 50409
💡 How to use:
These links will start a conversation with ResistBot. When prompted, mention S. 3302 to reference this bill.
Contact Your Representatives
Write to YOUR elected officials about this bill
Rate This Bill
Sign in to save a private rating for this bill and track your civic engagement over time.
Sign In FreePolicy Topics
Timeline
December 2, 2025
Bill Introduced
Current
Referred to Committee
June 12, 2026
Last Updated
Ask the Constitutional AI About This Bill
Sign in free to chat with our constitutional analysis AI about this bill — get plain-English explanations, constitutional concerns, and demographic impact estimates personalized to you.
Sign In Free to Chat